Cotinga Pharmaceuticalsの収益
Cotinga Pharmaceuticalsの収益は何ですか。
Cotinga Pharmaceuticals, Inc.の収益はN/Aです。
収益の定義は何ですか。
収入とは、企業が通常の事業活動から得た収入であり、通常は商品やサービスの顧客への売却による収入です。
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Cotinga Pharmaceuticalsは何をしますか。
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.